Table 1 Baseline demographics and clinical characteristics

From: Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis

Parameter

All tirzepatide N = 4,887

All comparator N = 2,328

Total N = 7,215

Age, years

58.7 (9.9)

59.0 (10.0)

58.8 (9.9)

Age category, n (%)

 <65 years

3,421 (68.5)

1,496 (67.7)

4,917 (68.1)

 ≥65 years

1,466 (31.5)

832 (32.3)

2,298 (31.9)

 Sex, female, n (%)

2,163 (43.8)

962 (42.6)

3,125 (43.3)

Ethnicity, n (%)

 Hispanic or Latino

2,039 (42.3)

1,020 (42.8)

3,059 (42.4)

 Not Hispanic or Latino

2,212 (45.8)

1,091 (45.6)

3,303 (45.8)

 Not reported

636 (11.9)

217 (11.7)

853 (11.8)

Race, n (%)

 American Indian or Alaska Native

356 (7.4)

164 (6.7)

520 (7.2)

 Asian

792 (15.1)

273 (14.1)

1,065 (14.8)

 Black or African American

185 (3.8)

69 (2.9)

254 (3.5)

 Native Hawaiian or Other Pacific Islander or Multiple

44 (1.0)

36 (1.3)

80 (1.1)

 White

3,507 (72.6)

1,783 (75.1)

5,290 (73.4)

Country, n (%)

 United States

1,084 (21.7)

503 (22.9)

1,587 (22.0)

 Outside United States

3,803 (78.3)

1,825 (77.1)

5,628 (78.0)

 Weight, kg

91.12 (20.32)

90.59 (20.36)

90.98 (20.37)

 BMI, kg m2

32.849 (6.263)

32.673 (6.259)

32.791 (6.262)

 Duration of diabetes, years

9.23 (6.81)

9.22 (6.78)

9.26 (6.83)

 HbA1c, %

8.30 (0.94)

8.27 (0.91)

8.29 (0.93)

HbA1c category, n (%)

 ≤8.5%

3,177 (64.2)

1475 (64.9)

4,652 (64.5)

 >8.5%

1,709 (35.8)

853 (35.1)

2,562 (35.5)

Systolic blood pressure, mmHg

131.88 (14.41)

132.02 (14.58)

131.94 (14.49)

Diastolic blood pressure, mmHg

79.22 (9.28)

79.36 (9.40)

79.26 (9.34)

HDL cholesterol, mg dl−1

44.60 (11.81)

44.86 (11.52)

44.67 (11.73)

LDL cholesterol, mg dl−1

93.07 (34.49)

94.28 (34.85)

93.45 (34.63)

Triglycerides, mg dl−1

185.67 (131.72)

181.61 (134.30)

184.53 (133.16)

Total cholesterol, mg dl−1

173.18 (41.76)

173.90 (42.02)

173.40 (41.88)

Smoking history, yes, n (%)

1,453 (30.7)

719 (28.9)

2,172 (30.1)

Current smoking status, yes, n (%)

822 (16.6)

416 (18.5)

1238 (17.2)

UACR, mg g−1, median

11.0

12.0

12.0

UACR category, n (%)

 Microalbuminuria

1,156 (24.2)

560 (23.4)

1,716 (24.0)

 Macroalbuminuria

258 (5.6)

123 (4.6)

381 (5.3)

 eGFR, ml/min/1.73 m2

89.02 (18.88)

88.99 (18.60)

89.04 (18.76)

eGFR category, n (%)

 <60 ml/min/1.73 m2

363 (8.4)

233 (8.2)

596 (8.3)

 ≥60 ml/min/1.73 m2

4,523 (91.6)

2,094 (91.8)

6,617 (91.7)

  1. Data are presented as mean (s.d.) unless otherwise indicated (mITT population). Percentage is based on the number of participants with non-missing measurement at baseline. Data are strata size adjusted estimate. Strata are defined as trial-level cardiovascular risk (SURPASS-4 forms one stratum, and all other trials form one stratum). eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; N, number of participants in the population; n, number of participants in the specified category; UACR, urine albumin to creatinine ratio.